Want to see ACET full AI Analyst Report?
ACET Stock Chart & Stats
$9.00
-$0.63(-7.48%)
At close: 4:00 PM EDT
$9.00
-$0.63(-7.48%)
Day’s Range― - ―
52-Week Range$6.01 - $17.43
Previous Close$7.79
Volume71.21K
Average Volume (3M)94.19K
Market Cap
$86.69M
Enterprise Value-$12.49
Total Cash (Recent Filing)$118.19M
Total Debt (Recent Filing)$12.85M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Nov 11, 2026EPS Estimate
-1.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.45
Shares Outstanding9,361,490
10 Day Avg. Volume107,080
30 Day Avg. Volume94,185
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.36
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$22.50Price Target Upside150.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-6.42
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageThe modest debt load reduces fixed financial obligations and leaves more flexibility to fund clinical programs. This is a durable balance-sheet advantage, although it does not eliminate the company’s need for additional capital.
Off-the-Shelf Cell Therapy PlatformAn allogeneic platform is designed for standardized, potentially scalable manufacturing rather than patient-specific production. If clinical efficacy is demonstrated, this model could support broader deployment and more efficient commercialization.
Narrowing Net LossesThe reduction in reported losses suggests some improvement in cost performance over the observed period. While profitability remains distant and cash burn is still substantial, sustained loss reduction could improve future operating leverage.
Bears Say
No Commercial RevenueWithout marketed products, Adicet lacks recurring operating revenue and must depend on clinical success, partnerships, or financing. This makes the business model highly exposed to development setbacks and delays before commercial validation.
Persistent Cash BurnHeavy operating and free-cash-flow deficits indicate that research and clinical activities currently consume substantial capital. Continued burn increases dependence on external funding and can constrain the pace or scope of future development.
Shrinking Equity BaseThe materially smaller equity base reflects sustained losses and reduces the company’s financial cushion. Combined with negative returns on equity, this erosion raises long-term financing risk and may increase reliance on potentially dilutive capital.
Adicet Bio News
ACET FAQ
What was Adicet Bio’s price range in the past 12 months?
Adicet Bio lowest stock price was $6.01 and its highest was $17.43 in the past 12 months.
What is Adicet Bio’s market cap?
Adicet Bio’s market cap is $86.69M.
When is Adicet Bio’s upcoming earnings report date?
Adicet Bio’s upcoming earnings report date is Nov 11, 2026 which is in 69 days.
How were Adicet Bio’s earnings last quarter?
Adicet Bio released its earnings results on Aug 05, 2026. The company reported -$1.99 earnings per share for the quarter, missing the consensus estimate of -$1.692 by -$0.298.
Is Adicet Bio overvalued?
According to Wall Street analysts Adicet Bio’s price is currently Undervalued.
Does Adicet Bio pay dividends?
Adicet Bio pays a Quarterly dividend of $0.01 which represents an annual dividend yield of N/A. See more information on Adicet Bio dividends here
What is Adicet Bio’s EPS estimate?
Adicet Bio’s EPS estimate is -1.59.
How many shares outstanding does Adicet Bio have?
Adicet Bio has 9,361,490 shares outstanding.
What happened to Adicet Bio’s price movement after its last earnings report?
Adicet Bio reported an EPS of -$1.99 in its last earnings report, missing expectations of -$1.692. Following the earnings report the stock price went down -13.428%.
Which hedge fund is a major shareholder of Adicet Bio?
Currently, no hedge funds are holding shares in ACET
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Adicet Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.50 (150.00% Upside)
$22.50 (150.00% Upside)
Blogger Sentiment
Bullish
ACET Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 563.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.19%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Adicet Bio
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
ACET Stock 12 Month Forecast
Average Price Target
$22.50
▲(150.00% Upside)
Technical Analysis
Sutro Biopharma
―
PMV Pharmaceuticals
―
Gain Therapeutics
―
Immix Biopharma
―
Artiva Biotherapeutics, Inc.
―
Ownership Overview
21.99% Insiders
9.73% Mutual Funds
35.57% Other Institutional Investors
28.46% Public Companies and
Individual Investors